Randomized, Double-masked, Placebo-controlled Clinical Trial on the Effects of Propolis and Chlorhexidine Mouthrinses on Gingivitis

Objective: The aim of this study was to compare the effects of typified propolis and chlorhexidine mouthrinses on gingival health in a randomized double-masked placebo-controlled clinical trial.Methods: Sixty participants were randomized to 3 mouthrinse study groups: 1) 2% typified propolis (n=20); 2) 0.12% chlorhexidine (n=20), and 3) placebo (n=20). Participants rinsed unsupervised twice a day for 28 days. The Papillary Bleeding Score (PBS) was measured on the mesio-buccal surfaces of all teeth at baseline and 28 days thereafter. Co-variance analysis was employed to compare PBS average values and the number of sites with PBS ≥2 among study groups. Sub-group analysis was further applied to participants who were <40 years-old.Results: The results show efficacy of propolis mouthrinse when comparing before and after treatment protocols significantly for a reduction of mean PBS scores. When looking at younger participants after 28 days, propolis mouthrinse was superior to all groups in reducing mean PBS scores and significantly so when compared to 0.12% chlorhexidine mouthrinse.Conclusion: The efficacy of 2% typified propolis mouthrinse was demonstrated in reducing the levels of gingival inflammation. These results need to be duplicated by other investigators by employing similar study protocols.Descriptors: Randomized Clinical Trial, Propolis, Chlorhexidine, Gingivitis

Download Full-text

Comparison of a Novel Sonic Toothbrush to Manual Brushing on Plaque Control and Gingival Inflammation: A Multicenter, Randomized, Controlled Clinical Trial

The International Journal of Periodontics & Restorative Dentistry ◽

10.11607/prd.5363 ◽

2021 ◽

Vol 41 (1) ◽

pp. 99-104

Author(s):

Myron Nevins ◽

Chia-Yu Chen ◽

Eric Kerr ◽

Gerardo Mendoza-Azpur ◽

Gaetano Isola ◽

...

Keyword(s):

Clinical Trial ◽

Controlled Clinical Trial ◽

Randomized Controlled Clinical Trial ◽

Gingival Inflammation ◽

Randomized Controlled ◽

Plaque Control

Download Full-text

Comparing Efficacy and Safety of Oral Tranexamic Acid and 4% Topical Hydroquinone Cream in Melasma Treatment: A Randomized Controlled Clinical Trial and Review of Literature

Serbian Journal of Dermatology and Venerology ◽

10.2478/sjdv-2019-0017 ◽

2019 ◽

Vol 11 (4) ◽

pp. 119-128

Author(s):

Reza Yaghoobi ◽

Samin Vala ◽

Nader Pazyar ◽

Maryam Zeinali ◽

Saeed Hesam

Keyword(s):

Clinical Trial ◽

Tranexamic Acid ◽

Skin Pigmentation ◽

Severity Index ◽

Study Groups ◽

Controlled Clinical Trial ◽

Therapeutic Effects ◽

Common Skin ◽

The Difference ◽

Group B

AbstractIntroduction. Melasma is a common skin pigmentation disorder affecting a patient’s life psychologically and socially. Topical medications or lasers can have temporary and limited therapeutic effects on melasma. Material and Methods. This study is a prospective clinical trial comparing therapeutic effects of oral Tranexamic acid (TXA) and topical Hydroquinone (HQ) cream. A total number of 69 patients were examined. During the study, 10 patients failed to appear for the follow-up and 59 of them completed the trial. The patients were also divided randomly into two groups. Group A received TXA capsule 250 mg every 12 hours and group B received 4% topical HQ cream day and night. The patients from both groups were treated for 3 months. Melasma Area and Severity Index (MASI) scores were then calculated at the baseline, 4 weeks, and 12 weeks into the treatment and 3 months after the end of intervention. Results. MASI baseline, 4 weeks,12 weeks, and 24 weeks in TXA group were 21.66, 13.69, 9.10, 9.24; respectively. Reduction of MASI between baseline and 4 weeks was statistically significant. Such a decreasing trend in MASI scores between baseline and 12 weeks was also reported as statistically significant (p=0.001). In the HQ group, MASI baseline,4 weeks, 12 weeks, and 24 weeks were 21.46, 13.57, 10.93, 11.20; respectively. Reduction of MASI scores between baseline and 4 weeks was statistically significant. Moreover, a decline in MASI scores was observed between baseline and 12 weeks that was statistically significant (p=0.001). Considering both groups MASI scores were reduced but the difference between two study groups was not statistically significant (p=0.98). Conclusion. The efficacy of TXA and HQ was the same and both could significantly reduce MASI scores.

Download Full-text

Fluoxetine for Anterior Ischemic Optic Neuropathy (AION); a Double Blind Randomized Clinical Trial

10.21203/rs.3.rs-179574/v1 ◽

2021 ◽

Author(s):

Mohammad Hossein Abbasi ◽

Shahnaz Rimaz ◽

Zahra Pourmousa ◽

Leila Janani ◽

Mostafa Soltan Sanjari

Keyword(s):

Clinical Trial ◽

Randomized Clinical Trial ◽

Optic Neuropathy ◽

Study Groups ◽

Anterior Ischemic Optic Neuropathy ◽

Control Group ◽

Ischemic Optic Neuropathy ◽

Double Blind ◽

Clinical Prognosis ◽

Before And After

Abstract Background: Fluoxetine enhances the levels of brain-derived neurotrophic factor (BDNF); considering its known improving effects on neurogenesis and plasticity, it seems to improve the Anterior Ischemic Optic Neuropathy (AION). This study aimed to evaluate the effect of Fluoxetine on clinical prognosis of patients with AION.Methods: In this double-blind placebo-controlled randomized clinical trial, subjects with AION who were referred to Rasool Akram Hospital were divided into two study groups; the fluoxetine group that received 20 mg Fluoxetine daily(n=50) and the control group (n=50) that received placebo for a period of six months. Patients underwent clinical and paraclinical evaluations before and after the trial. This study was a registered trial with IRCT code IRCT20181109041596N1.Results: One hundred patients were enrolled from August 2019 to December 2020 and assessed in this study. Subjects in Fluoxetine group showed significant improvement in visual acuity in comparison to the placebo group with less score in LogMAR scale (P: 0.008 and 0.002, respectively), improvement in MD parameters of perimetry (P: 0.003 and 0.002, respectively), and decrease in VEP latencies (P (in 1st minute): <0.001 and <0.001, P (in 15st minute): 0.038 and 0.011, respectively). There were no differences in color vision, Rnfl in all dimensions, PSD parameter of perimetry or VEP amplitudes following the trial of Fluoxetine therapy (Ps> 0.05).Conclusion: Fluoxetine showed promising therapeutic value for patients with AION besides its safety as an additive treatment option to corticosteroids.

Download Full-text

Transcranial magnetic stimulation associated with manual therapy in patients with knee osteoarthritis: a randomized controlled clinical trial protocol

Manual Therapy Posturology & Rehabilitation Journal ◽

10.17784/mtprehabjournal.2018.16.608 ◽

2020 ◽

pp. 1-4

Author(s):

Mannaly Mendonça ◽

Maria das Graças Araújo ◽

Camilla Fonseca ◽

Maíra Lima, Luiz Mèlo ◽

Sérgio Rocha ◽

...

Keyword(s):

Clinical Trial ◽

Transcranial Magnetic Stimulation ◽

Knee Osteoarthritis ◽

Manual Therapy ◽

Magnetic Stimulation ◽

Treatment Protocol ◽

Controlled Clinical Trial ◽

Knee Oa ◽

Before And After ◽

Registration Number

Background: Persistent pain in knee osteoarthritis (KOA) may generate sensitization of the afferent and central nervous system (CNS) pathways over time. Therefore, for patients with chronic pain derived from KOA, to associate therapies that address peripheral impairment, such as central and manual therapy and transcranial magnetic stimulation seems to be a promising strategy for pain reduction. Objectives: The purpose of this study is to unite rTMS and TM to control the pain of patients with knee OA and to examine the efficacy of this treatment protocol, assuming that this union would be more beneficial than the formally applied therapies isolated. Methods: This clinical trial with three arms interventions, controlled, triple blind and randomized, will allocate patients with KOA in groups (i) transcranial magnetic stimulation; (ii) sham transcranial magnetic stimulation + manual therapy and (iii) transcranial magnetic stimulation + manual therapy. Pain assessment will be performed using the visual analog scale of pain of 100 points, before and after the interventions, and for a maximum of 30 days after the single session. This session will involve the application of real or fictitious transcranial magnetic stimulation followed by manual or home therapy. Discussion: The study is in the recruitment stage and it is expected that after the application of the therapeutic protocol the group that performed the association has a more significant improvement in comparison to the others. Study registry: The protocol of this study was published on the Clinical Trials (www.clinicaltrials.org), with the registration number NCT03076294.

Download Full-text

Efficacy of a novel post‐foaming dental gel on gingival inflammation: A randomized controlled clinical trial

Journal of Periodontology ◽

10.1002/jper.19-0594 ◽

2020 ◽

Vol 91 (12) ◽

pp. 1569-1583

Author(s):

Jonathan B. Levine ◽

Jordan Goncalves ◽

Daniel Nguyen ◽

Olivia Nguyen ◽

Hatice Hasturk

Keyword(s):

Clinical Trial ◽

Controlled Clinical Trial ◽

Randomized Controlled Clinical Trial ◽

Gingival Inflammation ◽

Randomized Controlled

Download Full-text

Image-guided versus palpation-guided injections for the treatment of chronic lateral epicondylopathy: a randomized controlled clinical trial

Handchirurgie · Mikrochirurgie · Plastische Chirurgie ◽

10.1055/a-0732-5556 ◽

2018 ◽

Vol 50 (05) ◽

pp. 348-352 ◽

Cited By ~ 2

Author(s):

Michael-Alexander Malahias ◽

Maria-Kyriaki Kaseta ◽

Sotirios-Tsambikos Kazas ◽

Panayiotis D Megaloikonomos ◽

Andreas F Mavrogenis ◽

...

Keyword(s):

Clinical Trial ◽

Statistical Difference ◽

Lateral Epicondylitis ◽

T Test ◽

Controlled Clinical Trial ◽

Ultrasound Guided ◽

Chi Square ◽

Before And After ◽

Group A ◽

Group B

Abstract Background There have been several studies published comparing the ultrasound-guided with the “blind” infiltrations in the shoulder’s area. On the contrary, there is only very limited data regarding the necessity of ultrasound guidance in lateral epicondylitis. Materials and Methods A prospective, randomized, blinded at initial and follow-up evaluation, comparative clinical trial was conducted, involving 44 patients with a history of chronic persistent epicondylopathy. The patients were randomly divided into 2 groups of 22 people each. Group A patients underwent three ultrasound-guided betamethazone injections, while group B included those who underwent three “blind” injections, centered at the palpable point of maximum pain. The evaluation was done before and after (4 and 12 weeks) the injections using the Visual Analogue Scale for pain (VAS, 0–10) and the Roles & Maudsley score. Results There was not any significant statistical difference between the two groups as for mean VAS at 4 weeks (p = 0.150, t-test) and mean VAS at 12 weeks (p = 0.286, t-test). Furthermore, the final success rate, as measured by the Roles & Maudsley score, was slightly superior in group B (67 % of the patients with excellent or good results) when compared with group A (46 % of the patients), but without any statistical difference (p = 0.161, chi-square). Conclusion Our trial proved that an ultrasound-guided injection is not superior than a palpation-guided injection of corticosteroids in the treatment of lateral epicondylopathy.

Download Full-text